Asthma Clinical Trial
— PASSPORTOfficial title:
Physiology and Structure of the Small Airways in Patients With Chronic Airflow Obstruction or COVID-19
NCT number | NCT04716023 |
Other study ID # | 18IC4688 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | August 23, 2019 |
Est. completion date | February 2, 2022 |
The purpose of this research project is to study small airways physiological function in patients with chronic obstructive lung disease or COVID-19 and explore the relationship with in-vivo microanatomical small airway structure as measured by OCT. Correlating endobronchial assessment with multiple breath nitrogen washout and impulse oscillometry will allow the characterisation of the relationship between small airway structural findings and these validated investigations. A small volume lung wash, endobronchial brushings and the collection of a limited number of endobronchial cryobiopsy samples will be performed to better understand the endobronchial environment of the small airways through inflammatory studies. Following the completion of any such work, residual samples will be stored in a "bio-bank" to enable the completion of future work. Understanding the relationship with symptom-based quality of life scoring questionnaires and a functional assessment of exercise capacity will help elucidate the clinical impact of in-vivo small airways findings.
Status | Recruiting |
Enrollment | 42 |
Est. completion date | February 2, 2022 |
Est. primary completion date | August 22, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria: 1. Age 16 or over 2. Scheduled for bronchoscopy as part of clinical care or research protocol 3. No bleeding diathesis or therapeutic anticoagulation 4. COPD: - FEV1/FVC ratio <70% or Asthma: - Diagnosed by standard clinical methods - Post-bronchodilator FEV1 =60% predicted or COVID-19 infection or previous COVID-19 infection (confirmed as per local guidelines) Exclusion Criteria: 1. Unable to provide informed consent 2. Exacerbation of obstructive airways disease or respiratory infection requiring systemic antibiotics or corticosteroids in the 6 weeks prior to enrolment unless suffering from COVID-19 infection and bronchoscopy is required for clinical reasons 3. Contra-indications to performing lung function testing - Aortic aneurysm >6cm - Unstable cardiovascular disease (unstable angina, myocardial infarction or pulmonary embolism <4 weeks prior) - Severe aortic stenosis - Pneumothorax - Cerebral aneurysm - Thoracic or abdominal surgery <4 weeks prior 4. Contra-indications to passing oesophageal balloons - Oesophageal ulceration or varices - Sinusitis, recent nasal surgery or epistaxis |
Country | Name | City | State |
---|---|---|---|
United Kingdom | The Royal Brompton | London |
Lead Sponsor | Collaborator |
---|---|
Imperial College London |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Exploratory: Inflammatory and pathological studies of airways brush, wash and cryobiopsy samples | Laboratory based scientific studies | Baseline, during the procedure | |
Primary | Respiratory resistance at 5Hz - 20Hz (R5-R20) (kPa/l/s) related to airtrapping as determined by quantitative CT (Expiratory phase low attenuation area <856 HU (%LAA <856 HU) | Impulse Oscillometry | Baseline, pre-procedure | |
Secondary | Respiratory reactance at 5Hz: X5 (kPa/l/s) | Impulse Oscillometry | Baseline, pre-procedure | |
Secondary | Reactance area: Ax (kPa/l/s) | Impulse Oscillometry | Baseline, pre-procedure | |
Secondary | Functional residual capacity by MBNW: FRCgas (L) | Multiple Breath Nitrogen Washout | Baseline, pre-procedure | |
Secondary | Lung clearance index: LCI | Multiple Breath Nitrogen Washout | Baseline, pre-procedure | |
Secondary | Ventilation heterogeneity conducting airways: Scond (L/s) | Multiple Breath Nitrogen Washout | Baseline, pre-procedure | |
Secondary | Ventilation heterogeneity acinar airways: Sacin (L/s) | Multiple Breath Nitrogen Washout | Baseline, pre-procedure | |
Secondary | Forced expiratory volume in 1 second: FEV1 (L) | Spirometry | Baseline, pre-procedure | |
Secondary | Forced vital capacity: FVC (L) | Spirometry | Baseline, pre-procedure | |
Secondary | Total lung capacity: TLC (L) | Plethysmography | Baseline, pre-procedure | |
Secondary | Residual volume: RV (L) | Plethysmography | Baseline, pre-procedure | |
Secondary | Functional residual capacity by plethysmography: FRCpleth (L) | plethysmography | Baseline, pre-procedure | |
Secondary | Airway mean luminal diameter (Dmean) | Optical Coherence Tomography | Baseline, during the procedure | |
Secondary | Airway inner lumen area (Ai) | Optical Coherence Tomography | Baseline, during the procedure | |
Secondary | Airway wall area (Aw), airway wall percentage (Aw%) as determined by [Aw/(Ai + Aw) × 100%] | Optical Coherence Tomography | Baseline, during the procedure | |
Secondary | Air trapping - expiratory phase low attenuation area <856 HU (%LAA <856 HU) | Quantitative CT | Baseline, pre-procedure | |
Secondary | Modified MRC dyspnoea score | Patient reported outcome measure | Baseline, pre-procedure | |
Secondary | St George's Respiratory Questionnaire Score | Patient reported outcome measure | Baseline, pre-procedure | |
Secondary | Asthma-related Quality of Life Questionnaire (AQLQ) (if asthmatic) | Patient reported outcome measure | Baseline, pre-procedure | |
Secondary | Asthma Control Questionnaire (ACQ) (if asthmatic) | Patient reported outcome measure | Baseline, pre-procedure | |
Secondary | 6-minute walk distance (m) | 6-minute walk distance (m) | Baseline, pre-procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|